<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17170" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Renal Transplantation Rejection</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Naik</surname>
            <given-names>Ruchi H.</given-names>
          </name>
          <aff>Vanderbilt University Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Shawar</surname>
            <given-names>Saed H.</given-names>
          </name>
          <aff>Vanderbilt University Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ruchi Naik declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Saed Shawar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>9</day>
          <month>2</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17170.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Various factors merit consideration in matching the donor kidney with the recipient, as the donor kidney acts as an alloantigen. In general, when transplanting tissue or cells from a genetically different donor to the graft recipient, the alloantigen of the donor induces an immune response in the recipient against the graft. This response can destroy the graft if not controlled. The whole process is called allograft rejection. This activity describes and defines the types of rejections and the evaluation and management of this condition and highlights the role of the interprofessional team in the care of patients with renal transplant rejection.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the pathophysiology of renal transplant rejection.</p></list-item><list-item><p>Assess&#x000a0;the appropriate evaluation of renal transplant rejection.</p></list-item><list-item><p>Evaluate&#x000a0;the treatment and management options available for renal transplant rejection.</p></list-item><list-item><p>Communicate&#x000a0;some interprofessional team strategies for improving care coordination to enhance the care of renal transplant rejection and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17170&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17170">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17170.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Kidney transplantation is the treatment of choice in patients with&#x000a0;end-stage renal disease or severe chronic kidney disease as it improves the quality of life and has better survival advantages compared to dialysis. Various factors merit consideration in matching the donor kidney with the recipient, as the donor kidney&#x000a0;acts as an alloantigen.&#x000a0;In general, when transplanting tissue or cells from a genetically different donor to the graft recipient, the alloantigen of the donor induces an immune response in the recipient against the graft. This response can destroy the graft if not controlled. The whole process is called allograft rejection.<xref ref-type="bibr" rid="article-17170.r1">[1]</xref>&#x000a0;Allograft rejection is inflammation with specific pathologic changes in the allograft due to the recipient&#x02019;s immune system recognizing the non-self antigen in the allograft, with or without dysfunction of the allograft. Both innate and adaptive immune systems play a significant role in rejection, but the T lymphocytes are the principal cells that recognize the allograft.&#x000a0;There are other costimulatory molecules, and cytokines also play a major role in this reaction. Depending on the histopathology and immunological characteristics, renal transplant rejections can be classified broadly under the following categories:</p>
        <list list-type="order">
          <list-item>
            <p>Hyperacute rejection: This happens minutes after transplant, and it is related to the preformed antibody or ABO incompatibility; this is rarely seen now due to the very sensitive cross-match tests performed before the transplant.</p>
          </list-item>
          <list-item>
            <p>Acute rejection: This can happen any time after transplant, usually within days to weeks after the transplant. It classifies into the following:
<list list-type="order"><list-item><p>Antibody-mediated rejection (ABMR) usually demonstrates evidence of circulating donor-specific alloantibodies and immunological evidence of antibody-mediated injuries to the kidney, such as inflammation of glomeruli (glomerulitis) or peritubular capillaries (peritubular capillaritis).</p></list-item><list-item><p>Acute T-cell-mediated rejection (TCMR) is characterized by lymphocytic infiltration of the tubules, interstitium, and sometimes the arterial intima.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Chronic rejection: It usually develops more than&#x000a0;3 months after transplant. It can be chronic antibody-mediated rejection or chronic T cell-mediated rejection.</p>
          </list-item>
          <list-item>
            <p>A mixture of acute rejection superimposed on chronic rejection.<xref ref-type="bibr" rid="article-17170.r2">[2]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17170.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Certain factors correlate with an increased risk of rejection of the renal allograft after the transplantation. These factors are:</p>
        <list list-type="bullet">
          <list-item>
            <p>Prior sensitization - high panel reactive antibodies</p>
          </list-item>
          <list-item>
            <p>Type of transplant: A deceased donor has a higher rejection than a living transplant</p>
          </list-item>
          <list-item>
            <p>The advanced age of the donor</p>
          </list-item>
          <list-item>
            <p>Prolonged cold ischemia time</p>
          </list-item>
          <list-item>
            <p>Prolonged warm ischemia time<xref ref-type="bibr" rid="article-17170.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>HLA mismatch</p>
          </list-item>
          <list-item>
            <p>Positive B cell crossmatch</p>
          </list-item>
          <list-item>
            <p>ABO incompatibility</p>
          </list-item>
          <list-item>
            <p>Recipient&#x02019;s age: Younger recipients have more rejection than older ones</p>
          </list-item>
          <list-item>
            <p>Recipient&#x02019;s race:&#x000a0;Black race&#x000a0;greater than&#x000a0;White race</p>
          </list-item>
          <list-item>
            <p>Delayed graft function</p>
          </list-item>
          <list-item>
            <p>Therapy non-compliance</p>
          </list-item>
          <list-item>
            <p>Previous episodes of rejections</p>
          </list-item>
          <list-item>
            <p>Inadequate immunosuppression<xref ref-type="bibr" rid="article-17170.r2">[2]</xref><xref ref-type="bibr" rid="article-17170.r4">[4]</xref><xref ref-type="bibr" rid="article-17170.r5">[5]</xref>&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17170.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The overall incidence and prevalence of acute allograft rejection have decreased, and graft survival has improved with more advanced and potent immunosuppressive&#x000a0;agents for induction and&#x000a0;maintenance therapy.&#x000a0;The incidence of acute rejection within the first year is around 7.9%.&#x000a0;Overall, the rate of acute rejection is lower in living-donor than deceased-donor kidney transplants; this is likely related to better matching and less cold ischemia time.<xref ref-type="bibr" rid="article-17170.r6">[6]</xref></p>
      </sec>
      <sec id="article-17170.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Renal transplant rejection, as stated earlier, is an immunological response that leads to inflammation with specific pathological changes in the allograft due to the recipient&#x02019;s immune system recognizing the non-self (foreign) antigen in the allograft. There are different mechanisms postulated depending on the type of rejection, as follows:</p>
        <list list-type="order">
          <list-item>
            <p>Hyperacute rejection: It is related to preexisting circulating antibodies in the recipient&#x02019;s blood against the donor antigen (usually ABO blood group or HLA antigen), which is present at the time of transplantation. These antibodies attack and destroy the transplanted organ as soon as or within a few hours after the allograft is revascularized.</p>
          </list-item>
          <list-item>
            <p>Acute T cell-mediated rejection: In which the recipient&#x02019;s lymphocytes become activated by recognition of foreign (non-self) donor antigens in the transplanted organ by antigen-presenting cells (APC) through direct, semi-direct or indirect pathways, which leads to activation and infiltration of the T cells and damage to the allograft.</p>
          </list-item>
          <list-item>
            <p>ABMR: It is related to antibodies against foreign (non-self) donor antigens, mainly HLA antigen, which leads to damage to the allograft through activation of the complement-dependent pathway as well as independent mechanisms recruiting natural killer cells (NK) cells, polymorphonuclear cells, platelets, and macrophages to attack the allograft. These antibodies can either preexist at a low level before the transplant or be synthesized de novo post-transplant.</p>
          </list-item>
          <list-item>
            <p>Chronic rejection is related to both immune and nonimmune-mediated factors. The primary risk factor for chronic rejection is non-compliance with immunosuppressive medication. It can be either chronic antibody-mediated rejection, mainly related to the presence of donor HLA-antigens donor-specific antibody (DSA), or chronic cellular rejection, which is uncommon.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17170.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>The standard way to detect rejection is a renal allograft biopsy, which accurately grades the severity of rejection, differentiates between different types and guides the treatment. There are&#x000a0;2 major classifications for the histopathological diagnosis of renal allograft biopsy: The Banff classification system and the Cooperative Clinical Trials in Transplantation (CCTT). Later, both were incorporated into the Banff 97 classification to standardize the histopathological diagnosis of renal allograft biopsy. Subsequently, Banff has had updates at regular intervals; the last&#x000a0;1 was in 2017. When performing a kidney biopsy, it should have adequate tissue to give a definitive interpretation. Adequate core biopsy must contain&#x000a0;10 glomeruli and&#x000a0;2 arteries and a section thickness of 3&#x000a0;to 4 microns&#x000a0;(marginal if 7&#x000a0;to 10 glomeruli and&#x000a0;1 artery; unsatisfactory if&#x000a0;less than&#x000a0;7 glomeruli or no arteries).<xref ref-type="bibr" rid="article-17170.r7">[7]</xref>&#x000a0;The histological characteristics of each type of rejection are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Hyperacute Rejection</bold>: The transplanted kidney turns mottled, dusky, and black as soon as it is revascularized. Severe endothelial injury, polymorphonuclear (PMN) infiltration, whispered thrombosis, and ischemic tissue necrosis would appear on the biopsy.</p>
          </list-item>
          <list-item>
            <p><bold>ABMR</bold>: Histological features of ABMR include arteriolar fibrinoid necrosis, fibrin thrombi in glomerular capillaries, glomerulitis, peritubular capillaritis, and interstitial hemorrhage. Also, the presence of peritubular capillary linear staining for C4d, a degradation product of the complement pathway that binds covalently to the endothelium, is highly suggestive of ABMR.</p>
          </list-item>
          <list-item>
            <p><bold>Acute T Cell-Mediated Rejection</bold>: Characterized by diffuse lymphocytic infiltration in the tubule, interstitium of the kidney, and, in severe cases, vessels of the allograft</p>
          </list-item>
          <list-item>
            <p><bold>Chronic Rejection Lesions:</bold>&#x000a0;These include interstitial fibrosis, tubular atrophy, vascular fibrous intimal thickening, glomerular basement membrane double contouring (transplant glomerulopathy), arteriolar hyalinosis, and hyaline arteriolar thickening.</p>
          </list-item>
        </list>
        <p>The Banff system uses scores to assess the presence and the degree of histopathological changes in the different compartments of renal transplant biopsies. It focuses mostly, but not exclusively, on the diagnostic features seen in rejection. The staging is below according to the scoring of the various lesions described above.</p>
        <list list-type="bullet">
          <list-item>
            <p>Category 1: Normal biopsy or nonspecific changes</p>
          </list-item>
          <list-item>
            <p>Category 2: Antibody-mediated rejection - AMR: depending on the features of the lesion, further divided into acute AMR, chronic AMR, or active chronic AMR</p>
          </list-item>
          <list-item>
            <p>Category 3: Suspicious (borderline) for acute T cell-mediated rejection - TCMR.</p>
          </list-item>
          <list-item>
            <p>Category 4: TCMR. Depending on the score of chronic lesions, it further divides into acute TCMR, chronic TCMR, or acute chronic TCMR</p>
          </list-item>
          <list-item>
            <p>Category 5: Interstitial fibrosis and tubular atrophy - IFTA</p>
          </list-item>
          <list-item>
            <p>Category 6: Other changes not considered to be the result of acute or chronic rejection<xref ref-type="bibr" rid="article-17170.r8">[8]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17170.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Most patients who have acute rejection episodes are asymptomatic and have abnormal allograft dysfunction, as evidenced by routine blood evaluation. When serum creatinine suddenly rises to more than 25% of the baseline value, the clinician should suspect allograft rejection. Even when creatinine does not trend down as expected in the early post-transplant phase, the possibility of rejection should be considered. Any new-onset or worsening proteinuria and new-onset or worsening hypertension should raise the suspicion of rejection. Sometimes a rejecting graft may present with fever, pain at the graft site, hematuria, dysuria, hypertension, fluid retention, and decreased urine output.<xref ref-type="bibr" rid="article-17170.r2">[2]</xref></p>
      </sec>
      <sec id="article-17170.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The approach for elevated serum creatinine in a renal transplant recipient would be the same as evaluating for acute kidney injury (AKI) with added workup for&#x000a0;the rejection. The specific workup for evaluating allograft dysfunction should include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Rule out prerenal causes: Check orthostatic vital signs, blood pressure, and volume status</p>
          </list-item>
          <list-item>
            <p>Rule out post-renal causes, mainly obstructive uropathy in older adults, by bladder scan, renal ultrasound (US)</p>
          </list-item>
          <list-item>
            <p>Complete blood count: Look for anemia and thrombocytopenia to rule out thrombotic microangiopathy (TMA)</p>
          </list-item>
          <list-item>
            <p>Electrolyte abnormality related to chronic kidney disease (CKD) and AKI</p>
          </list-item>
          <list-item>
            <p>Urinalysis (UA) and urine culture: It is essential to rule out infection as a cause of AKI</p>
          </list-item>
          <list-item>
            <p>Check for proteinuria: Either urine protein/creatinine ratio (UPCR) or 24-hour urine collection as nephrotic range proteinuria correlates with the presence of extensive transplant glomerulopathy</p>
          </list-item>
          <list-item>
            <p>Check for BK polyomavirus, cytomegalovirus (CMV) polymerase chain reaction (PCR) in clinically indicated patients</p>
          </list-item>
          <list-item>
            <p>Testing for&#x000a0;donor-specific antibodies</p>
          </list-item>
          <list-item>
            <p>Transplant renal ultrasound with Doppler for renal arterial and venous indices</p>
          </list-item>
          <list-item>
            <p>Many transplant centers use testing for donor-derived free DNA testing. This test can be positive even before the actual rise in serum creatinine, suggesting possible rejection.<xref ref-type="bibr" rid="article-17170.r9">[9]</xref>&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17170.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The treatment plan determination uses multiple factors, including the type of rejection, the severity of the histological lesion, the chronicity score,&#x000a0;and the recipient's comorbidity. What is discussed is a general guideline, but tailoring medical treatment to individual characteristics is needed.<xref ref-type="bibr" rid="article-17170.r10">[10]</xref><xref ref-type="bibr" rid="article-17170.r11">[11]</xref></p>
        <p><bold>1. Hyperacute Rejection</bold>: No effective therapy usually leads to early allograft nephrectomy, so prevention is the key by assuring the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>ABO compatibility between donor and recipient. Sometimes, it is advisable to address&#x000a0;ABO incompatibility under specific criteria, and careful pre-transplant preparation of the recipient with the removal of anti-ABO antibodies by plasmapheresis is an option, intravenous immunoglobulin (IVIG) with or without rituximab</p>
          </list-item>
          <list-item>
            <p>Pre-transplant cross-match (complement cell cytotoxicity test): Recipient serum is added to donor lymphocytes. If the test is positive (the recipient has an antibody that reacts with the donor HLA antigens on lymphocytes),&#x000a0;one should not proceed with transplant unless these antibodies are removable pre-transplant.</p>
          </list-item>
        </list>
        <p><bold>2. Antibody-Mediated Rejection</bold>:</p>
        <p>The treatment of acute antibody-mediated rejection also depends on the antibody levels. Higher antibody levels need plasma exchange for the removal of the antibodies. The following are the different modalities used for AMR:</p>
        <list list-type="bullet">
          <list-item>
            <p>Plasma exchange: 3&#x000a0;to 5 sessions daily on every other day are used for antibody removal, followed by IVIG and rituximab</p>
          </list-item>
          <list-item>
            <p>IVIG: IV immunoglobulin (100&#x000a0;to 200 mg/kg) is used, followed by the last session of plasma exchange when combined with plasmapheresis or a higher dose of 2g/kg after the final plasmapheresis.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Rituximab: Anti CD20 cell antibody rituximab (375 mg/m^2) is combined with IVIG, followed by plasma exchange</p>
          </list-item>
          <list-item>
            <p>Bortezomib: Plasma cell inhibitor bortezomib (1.3 mg/m^2) is also used in combination with plasma exchange and IVIG</p>
          </list-item>
          <list-item>
            <p>Splenectomy: A splenectomy is very rarely an option, but there are anecdotal reports of successful treatment of refractory rejections</p>
          </list-item>
          <list-item>
            <p>Optimize the dose and the level of the maintenance immunosuppressive drugs.</p>
          </list-item>
        </list>
        <p><bold>3. T Cell-Mediated rejection</bold>: They receive treatment with the following agents based on the severity of the lesion.</p>
        <list list-type="bullet">
          <list-item>
            <p>Methyl prednisone IV (250 to 1000 mg daily) targeting T cells, B cells, and macrophages; given for 3 to 5 days</p>
          </list-item>
          <list-item>
            <p>rATG - rabbit anti-thymocyte globulin IV (1&#x000a0;to 1.5 mg/kg) targeting T cell receptors. The duration varies among different transplant centers, but generally, it is for 7&#x000a0;to 14 doses based on the response and Cd3 level.</p>
          </list-item>
          <list-item>
            <p>Optimize the dose and the level of the maintenance immunosuppressive drugs.&#x000a0;</p>
          </list-item>
        </list>
        <p><bold>4. Chronic rejection</bold>: Since the antibody-mediated rejection mechanism is a major cause of chronic rejection, the same therapy as ABMR has been used, but generally, these measures are ineffective when&#x000a0;serum creatinine is over 3 mg/dl or heavy proteinuria is present.</p>
      </sec>
      <sec id="article-17170.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>While dealing with renal allograft dysfunction, equal weight should be given to find possible etiologies other than the rejection. The following are the most common reasons for allograft dysfunctions other than allograft rejection:</p>
        <p>
<bold>A. Immediate Post Transplant (less than&#x000a0;1 week)</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>Postischemic acute tubular necrosis or ischemia-reperfusion injury.</p>
          </list-item>
          <list-item>
            <p>Volume depletion leading to pre-renal AKI</p>
          </list-item>
          <list-item>
            <p>Surgical complications:
<list list-type="order"><list-item><p>Fluid collection &#x02013; urinoma, perinephric hematoma, or lymphocele</p></list-item><list-item><p>Vascular thrombosis - arterial and venous</p></list-item><list-item><p>Multiple renal arteries from the donor's kidney - infarction&#x000a0;of the part of the&#x000a0;allograft or necrosis of the ureter leading to urinary obstruction or urinary leak</p></list-item><list-item><p>Aeroembolism</p></list-item><list-item><p>Calcium oxalate crystals deposits in renal allograft</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>B. Early (1 week to 3 months) and Late Post Transplant (over&#x000a0;3 months)</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>Volume depletion</p>
          </list-item>
          <list-item>
            <p>Acute tubular necrosis</p>
          </list-item>
          <list-item>
            <p>Calcineurin inhibitor nephrotoxicity - manifesting as acute azotemia as well as chronic progressive renal disease.</p>
          </list-item>
          <list-item>
            <p>Urinary obstruction</p>
          </list-item>
          <list-item>
            <p>Infections
<list list-type="order"><list-item><p>Bacterial pyelonephritis</p></list-item><list-item><p>Viral infections - BK polyomavirus and CMVAcute and chronic interstitial nephritis</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Recurrent primary glomerular diseases&#x000a0;
<list list-type="order"><list-item><p>Focal segmental glomerulosclerosis (FSGS)</p></list-item><list-item><p>Primary membranous nephropathy</p></list-item><list-item><p>Diabetic nephropathy</p></list-item><list-item><p>Ig A nephropathy</p></list-item><list-item><p>C3 Glomerulonephritis (C3 GN)</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>De novo glomerular disease</p>
          </list-item>
          <list-item>
            <p>Thrombotic microangiopathy
<list list-type="order"><list-item><p>In patients with a prior history of thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), antiphospholipid antibody syndrome</p></list-item><list-item><p>Associated with&#x000a0;calcineurin inhibitor nephrotoxicity</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Transplant renal artery stenosis</p>
          </list-item>
          <list-item>
            <p>Post-transplant lymphoproliferative disease<xref ref-type="bibr" rid="article-17170.r12">[12]</xref>&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17170.s11" sec-type="Pertinent Studies and Ongoing Trials">
        <title>Pertinent Studies and Ongoing Trials</title>
        <p>Pertinent studies and ongoing trials on renal transplant rejection include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Small trials are ongoing for cell therapies to modulate the immune system.</p>
          </list-item>
          <list-item>
            <p>AntiCD40 monoclonal antibody (CFZ533) has the potential to block the co-stimulatory CD40&#x02013;CD154 pathway and is a possible upcoming clinical treatment for acute rejection.</p>
          </list-item>
          <list-item>
            <p>A few clinical trials are underway to check the safety and efficacy of immunomodulatory medicines for desensitization and antibody-medicated rejections.<xref ref-type="bibr" rid="article-17170.r13">[13]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17170.s12" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The acute rejections predispose to chronic graft dysfunction. T-cell-mediated rejections have better graft survival, especially when they respond to therapy and the serum creatinine reaches near the previous baseline after the treatment. Acute rejections occurring after&#x000a0;3 months, vascular rejections, and the rejections not responding to therapy (serum creatinine not reaching 75% of baseline value) are associated with poor graft survival. The appearance of de novo DSAs at any time post-transplant is associated with 5% poor graft outcome per year compared to recipients without these antibodies. Due to the above-mentioned graft outcomes, each acute rejection episode must be treated and monitored thoroughly by optimizing the maintenance immunosuppressive regimen.<xref ref-type="bibr" rid="article-17170.r14">[14]</xref><xref ref-type="bibr" rid="article-17170.r15">[15]</xref></p>
      </sec>
      <sec id="article-17170.s13" sec-type="Complications">
        <title>Complications</title>
        <p>The complication of acute rejection is graft failure if not treated appropriately and promptly. Even after the treatment, there is an association between poor graft survival after each rejection episode. The treatment of acute rejection, as described above,&#x000a0;results in&#x000a0;a severely immunocompromised state and puts the recipient at an increased risk from the side effects of the agents. There are many side effects associated with these immunosuppressive agents:</p>
        <list list-type="bullet">
          <list-item>
            <p>Increased cardiovascular risk</p>
          </list-item>
          <list-item>
            <p>Development of post-transplant diabetes mellitus</p>
          </list-item>
          <list-item>
            <p>Dyslipidemia</p>
          </list-item>
          <list-item>
            <p>Various malignancies (squamous cell carcinoma and post-transplant lymphoproliferative disease are the more common among them)</p>
          </list-item>
          <list-item>
            <p>Various opportunistic infections (viral- CMV, BK; fungal- histoplasmosis, coccidioidomycosis, etc, and other atypical organisms)</p>
          </list-item>
        </list>
        <p>CMV infection itself is also associated with an increased risk of rejection. Managing immunosuppressive agents after rejection episodes is always a double-edged sword. The clinician has to manage wisely while weighing the risks and benefits.</p>
      </sec>
      <sec id="article-17170.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Treatment noncompliance is&#x000a0;1 of the critical risk factors for the development of rejection, so patient education and awareness are key to preventing allograft rejection.</p>
      </sec>
      <sec id="article-17170.s15" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Key facts to keep in mind about renal transplant rejection include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Renal transplant rejections are either acute or chronic, and depending on the immunohistopathology, they are either antibody-mediated or T-cell-mediated rejections.</p>
          </list-item>
          <list-item>
            <p>Acute rejections usually present as an abrupt onset of allograft dysfunction, while chronic rejections present as a slow allograft dysfunction over time.</p>
          </list-item>
          <list-item>
            <p>Tissue biopsy is still the key to diagnosis, although a donor-derived free DNA detection test is emerging as a noninvasive tool for diagnosing rejections. However, it has not been validated to date.</p>
          </list-item>
          <list-item>
            <p>The treatment of rejection depends on the type, and it is managed with more immunosuppression and optimization of the baseline immunosuppressive regimen post-rejection.</p>
          </list-item>
          <list-item>
            <p>Although many factors play a role, patient awareness and education regarding compliance with the anti-rejection medication are still very important for the prevention of rejection.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17170.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Patients with renal transplants require a comprehensive interprofessional team approach in post-transplant care, including clinicians from different disciplines, nurses, social workers, and other health professionals. Together as a team, they play a significant role in better outcomes of renal allograft survival. While the transplant surgeon is the chief clinician, the specialty-trained transplant nurse provides invaluable support. This includes patient preparation, assisting during the surgery, and providing post-operative care. As the patient starts on post-procedure pharmacotherapy, a board-certified pharmacotherapy pharmacist should consult on the case to optimize agent selection and dosing and provide patient counsel. The transplant nurse monitors the patient and informs the treating clinician of any concerns or significant status changes. Given the lifelong follow-up necessary after a transplant, these players functioning as an interprofessional team on behalf of the patient optimize the outcomes with the new organ and minimize the chances of organ rejection.</p>
      </sec>
      <sec id="article-17170.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17170&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17170">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/kidney-health/renal-transplantation-rejection/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=17170">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17170/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17170">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17170.s18">
        <title>References</title>
        <ref id="article-17170.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nankivell</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Alexander</surname>
                <given-names>SI</given-names>
              </name>
            </person-group>
            <article-title>Rejection of the kidney allograft.</article-title>
            <source>N Engl J Med</source>
            <year>2010</year>
            <month>Oct</month>
            <day>07</day>
            <volume>363</volume>
            <issue>15</issue>
            <fpage>1451</fpage>
            <page-range>1451-62</page-range>
            <pub-id pub-id-type="pmid">20925547</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17170.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Joosten</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Sijpkens</surname>
                <given-names>YW</given-names>
              </name>
              <name>
                <surname>van Kooten</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Paul</surname>
                <given-names>LC</given-names>
              </name>
            </person-group>
            <article-title>Chronic renal allograft rejection: pathophysiologic considerations.</article-title>
            <source>Kidney Int</source>
            <year>2005</year>
            <month>Jul</month>
            <volume>68</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-13</page-range>
            <pub-id pub-id-type="pmid">15954891</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17170.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tennankore</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Alwayn</surname>
                <given-names>IP</given-names>
              </name>
              <name>
                <surname>Kiberd</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>Prolonged warm ischemia time is associated with graft failure and mortality after kidney transplantation.</article-title>
            <source>Kidney Int</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>89</volume>
            <issue>3</issue>
            <fpage>648</fpage>
            <page-range>648-58</page-range>
            <pub-id pub-id-type="pmid">26880458</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17170.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pallard&#x000f3; Mateu</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Sancho Calabuig</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Capdevila Plaza</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Franco Esteve</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Acute rejection and late renal transplant failure: risk factors and prognosis.</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2004</year>
            <month>Jun</month>
            <volume>19 Suppl 3</volume>
            <fpage>iii38</fpage>
            <page-range>iii38-42</page-range>
            <pub-id pub-id-type="pmid">15192134</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17170.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Terasaki</surname>
                <given-names>PI</given-names>
              </name>
              <name>
                <surname>Ozawa</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Predicting kidney graft failure by HLA antibodies: a prospective trial.</article-title>
            <source>Am J Transplant</source>
            <year>2004</year>
            <month>Mar</month>
            <volume>4</volume>
            <issue>3</issue>
            <fpage>438</fpage>
            <page-range>438-43</page-range>
            <pub-id pub-id-type="pmid">14961999</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17170.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hart</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Skeans</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Gustafson</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Cherikh</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Wainright</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Kucheryavaya</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Woodbury</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Snyder</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Kasiske</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Israni</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>OPTN/SRTR 2015 Annual Data Report: Kidney.</article-title>
            <source>Am J Transplant</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>17 Suppl 1</volume>
            <issue>Suppl 1</issue>
            <fpage>21</fpage>
            <page-range>21-116</page-range>
            <pub-id pub-id-type="pmid">28052609</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17170.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Colvin</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Saiontz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bonsib</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Buick</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Burke</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cavallo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Haas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lindblad</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Manivel</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Nast</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Salomon</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Weaver</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of pathologic criteria for acute renal allograft rejection: reproducibility, sensitivity, and clinical correlation.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>1997</year>
            <month>Dec</month>
            <volume>8</volume>
            <issue>12</issue>
            <fpage>1930</fpage>
            <page-range>1930-41</page-range>
            <pub-id pub-id-type="pmid">9402096</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17170.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roufosse</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Simmonds</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Clahsen-van Groningen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Haas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Henriksen</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Horsfield</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Loupy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mengel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Perkowska-Ptasi&#x00144;ska</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rabant</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Racusen</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Solez</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>JU</given-names>
              </name>
            </person-group>
            <article-title>A 2018 Reference Guide to the Banff Classification of Renal Allograft Pathology.</article-title>
            <source>Transplantation</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>102</volume>
            <issue>11</issue>
            <fpage>1795</fpage>
            <page-range>1795-1814</page-range>
            <pub-id pub-id-type="pmid">30028786</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17170.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bloom</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Bromberg</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Poggio</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Bunnapradist</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Langone</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Sood</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Matas</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mannon</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Sharfuddin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fischbach</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Narayanan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jordan</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Weir</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Hiller</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Prasad</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Woodward</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Grskovic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sninsky</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Yee</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Brennan</surname>
                <given-names>DC</given-names>
              </name>
              <collab>Circulating Donor-Derived Cell-Free DNA in Blood for Diagnosing Active Rejection in Kidney Transplant Recipients (DART) Study Investigators</collab>
            </person-group>
            <article-title>Cell-Free DNA and Active Rejection in Kidney Allografts.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>28</volume>
            <issue>7</issue>
            <fpage>2221</fpage>
            <page-range>2221-2232</page-range>
            <pub-id pub-id-type="pmid">28280140</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17170.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Webster</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tallapragada</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Carr</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2017</year>
            <month>Jul</month>
            <day>20</day>
            <volume>7</volume>
            <issue>7</issue>
            <fpage>CD004756</fpage>
            <pub-id pub-id-type="pmid">28731207</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17170.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharif</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shabir</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chand</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cockwell</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ball</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Borrows</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2011</year>
            <month>Nov</month>
            <volume>22</volume>
            <issue>11</issue>
            <fpage>2107</fpage>
            <page-range>2107-18</page-range>
            <pub-id pub-id-type="pmid">21949096</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17170.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stein</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>The effect of adrenaline and of alpha- and beta-adrenergic blocking agents on ATP concentration and on incorporation of 32Pi into ATP in rat fat cells.</article-title>
            <source>Biochem Pharmacol</source>
            <year>1975</year>
            <month>Sep</month>
            <day>15</day>
            <volume>24</volume>
            <issue>18</issue>
            <fpage>1659</fpage>
            <page-range>1659-62</page-range>
            <pub-id pub-id-type="pmid">12</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17170.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abramowicz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Oberbauer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Heemann</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Viklicky</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Peruzzi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mariat</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Crespo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Budde</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Oniscu</surname>
                <given-names>GC</given-names>
              </name>
            </person-group>
            <article-title>Recent advances in kidney transplantation: a viewpoint from the Descartes advisory board.</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2018</year>
            <month>Oct</month>
            <day>01</day>
            <volume>33</volume>
            <issue>10</issue>
            <fpage>1699</fpage>
            <page-range>1699-1707</page-range>
            <pub-id pub-id-type="pmid">29342289</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17170.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>El Ters</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Grande</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Keddis</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Rodrigo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chopra</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Dean</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Stegall</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Cosio</surname>
                <given-names>FG</given-names>
              </name>
            </person-group>
            <article-title>Kidney allograft survival after acute rejection, the value of follow-up biopsies.</article-title>
            <source>Am J Transplant</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>13</volume>
            <issue>9</issue>
            <fpage>2334</fpage>
            <page-range>2334-41</page-range>
            <pub-id pub-id-type="pmid">23865852</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17170.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hariharan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>McBride</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Cherikh</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Tolleris</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Bresnahan</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>CP</given-names>
              </name>
            </person-group>
            <article-title>Post-transplant renal function in the first year predicts long-term kidney transplant survival.</article-title>
            <source>Kidney Int</source>
            <year>2002</year>
            <month>Jul</month>
            <volume>62</volume>
            <issue>1</issue>
            <fpage>311</fpage>
            <page-range>311-8</page-range>
            <pub-id pub-id-type="pmid">12081593</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
